Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Profile Name||SMAD4 mutant|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|SMAD4 mutant||colorectal cancer||no benefit||Cetuximab||Clinical Study - Cohort||Actionable||In a clinical study, Chinese metastatic colorectal cancer patients harboring a SMAD4 mutation did not respond to treatment with Erbitux (cetuximab) and showed a shorter progression-free survival compared to patients with wild-type SMAD4 (median: 90 vs 250 days, p=0.0081) (PMID: 29703253).||29703253|
|SMAD4 mutant||stomach cancer||not applicable||N/A||Guideline||Risk Factor||Germline mutations in SMAD4 or BMPR1A result in juvenile polyposis syndrome, which is associated with increased risk of developing gastric cancer (NCCN.org).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|